Study by prominent Brigham scientists retracted due to compromised data

An internal investigation has found compromised data in a stem cell study led by prominent Brigham and Womens Hospital researchers, and the paper has been retracted. The authors claimed they had found evidence that the heart can regenerate at a rapid rate, contrary to years of belief that heart muscle cells cells turnover very slowly.

The paper, published in 2012 in the journal Circulation, was retracted Tuesday by the journals publisher, the American Heart Association.

This retraction is highly significant. In my 30 years in cardiovascular science I cannot recall a paper of similar prominence being retracted from Circulation, Dr. Charles Murry, co-director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington, wrote in an e-mail. This appears to settle the controversy about the rate of cell replacement in the human heart, i.e. it turns over every 60 years, not every 6 months.

The retraction comes in the wake of a major scandal that has unfolded over the last few months as a Japanese research institution found evidence of fabrication in a major stem cell paper led by a different Brigham scientist.

The journals retraction notice, first reported by the blog Retraction Watch, does not specify which researchers are at fault, but the paper involved several high-profile scientists including Dr. Piero Anversa, a cardiologist whose research has often raised questions from other scientists, and Dr. Joseph Loscalzo, chief of medicine at the Brigham.

According to the retraction notice, an ongoing institutional review by Harvard Medical School and Brigham and Womens Hospital has determined that the data are sufficiently compromised that a retraction is warranted.

A Brigham and Womens Hospital spokeswoman said a statement was forthcoming. Anversa and Loscalzo did not immediately reply to e-mails.

Dr. Jonas Frisn, a professor of stem cell research at the Karolinska Institute in Sweden, published a study in 2009 showing a very low rate of renewal of human heart muscle cellsaround 1 percent of cells turned over per year. That low rate was replicated in other laboratories.

But in 2012, Anversas laboratory used the same techniquemeasuring an isotope of carbon found in the nucleus of cellsto detect a much higher rate of heart muscle cell renewal, as much as 23 percent per year. The laboratory also found that the rate of renewal increased with age, contrary to what other scientists expected and found. Frisen said he and his colleagues read the paper extremely carefully, but could not make sense of it.

It wasnt possible from what they had written to understand exactly what they had done and how they had treated the data, Frisen said. He began corresponding with the authors, asking detailed questions about their methodology. He said there were some minor mistakes that appeared accidental, such as using the wrong units, and some things that may have stemmed from their unfamiliarity with using the technique. For example, he said the Brigham team didnt appear to have controlled for contamination.

Continue reading here:
Study by prominent Brigham scientists retracted due to compromised data

Japan stem cell researcher still backing discredited study

Haruko Obokata, center on stage, a researcher of Japanese government-funded laboratory Riken Center for Development Biology, bows in apology at the beginning of a press conference at a hotel in Osaka, western Japan Wednesday, April 9, 2014. The scientist accused of falsifying data in a widely heralded stem-cell research paper said that despite mistakes in her work the results are valid. AP

TOKYO -- The Japanese scientist accused of falsifying data in a widely heralded stem-cell research paper said Wednesday the results are valid despite mistakes in their presentation.

Haruko Obokata, 30, struggled to maintain her composure during a televised news conference packed with hundreds of reporters, but insisted she did not tamper with the data to fabricate results. She said she did not agree with retracting the research that appeared in the scientific journal Nature.

The phenomenon of ordinary cells transforming into stem cells under the influence of external stimulus was "confirmed many times for a fact," Obokata said at the press conference in the western city of Osaka. She said she could replicate her results again if allowed back into the lab to do so.

She has contested allegations of research malpractice made by a panel of scientists at the government-funded Riken Center for Development Biology, where she is employed.

Obokata said Riken had advised her not to speak publicly about the controversy. The event Wednesday, which lasted for over two hours, was her first public appearance in weeks and was made against doctors' orders after seeking hospital treatment Monday.

"I wasn't able to sleep well and was feeling worse and worse," she said. "I take this responsibility severely. I am deeply sorry."

Obokata apologized repeatedly for having used the wrong images and having altered an image in a report on using a simple lab procedure to grow tissue for treating illnesses such as diabetes and Parkinson's disease.

In an emailed statement, Riken reiterated Obokata's right to an appeal of its findings.

"Riken will give due consideration to the appeal in accordance with our regulations," it said.

Here is the original post:
Japan stem cell researcher still backing discredited study

Maligned stem cell researcher insists results valid

Elaine Kurtenbach, The Associated Press Published Wednesday, April 9, 2014 7:55AM EDT

TOKYO -- The Japanese scientist accused of falsifying data in a widely heralded stem-cell research paper said Wednesday the results are valid despite mistakes in presentation of the results.

Haruko Obokata, 30, struggled to maintain her composure during a televised news conference packed with hundreds of reporters, but insisted she did not tamper with the data to fabricate results. She said she did not agree with retracting the research that appeared in the scientific journal Nature.

The phenomenon of ordinary cells transforming into stem cells under the influence of external stimulus was "confirmed many times for a fact," Obokata said at the press conference in the western city of Osaka. She said she could replicate her results again if allowed back into the lab to do so.

She has contested allegations of research malpractice made by a panel of scientists at the government-funded Riken Center for Development Biology, where she is employed.

Obokata said Riken had advised her not to speak publicly about the controversy. The event Wednesday, which lasted for over two hours, was her first public appearance in weeks and was made against doctors' orders after seeking hospital treatment Monday.

"I wasn't able to sleep well and was feeling worse and worse," she said. "I take this responsibility severely. I am deeply sorry."

Obokata apologized repeatedly for having used the wrong images and having altered an image in a report on using a simple lab procedure to grow tissue for treating illnesses such as diabetes and Parkinson's disease.

In an emailed statement, Riken reiterated Obokata's right to an appeal of its findings.

"Riken will give due consideration to the appeal in accordance with our regulations," it said.

Continue reading here:
Maligned stem cell researcher insists results valid

Cell Surgical Network Opening in Australia

(PRWEB) April 08, 2014

CELL SURGICAL NETWORK

Originating in California, CSN is the worlds largest cell surgical network and first multidisciplinary Regenerative Medicine group. CSN is collaborating with the Australian Adult Stem Cell Foundation to bring the research network to Australia.

CSN HAS OVER 40 LOCATIONS within the United States and several more worldwide. CSN has recently been launched in Australia with hand selected approved board certified Physicians. The ASCF has played an important role to identifying physicians who are passionate about regenerative and integrated medicine with a strong interest in SVF cell transplants.

INTERNATIONAL PHYSICIAN GROUP- Physicians belonging to the CSN network join an international network of Board certified Physicians, creating a multidisciplinary team where they receive training, technology and IP transfer, education and support for physicians and staff, access to IRB approved research protocols, the opportunity to submit their own protocols for IRB approval, website presence, and access to a university quality research database that collects outcomes from all sites.

SVF PROCUREMENT- The CSN SVF isolation system is a completely closed sterile surgical procedure. There are no laboratory requirements (e.g. laminar flow hood or otherwise) avoiding issues of GMP maintenance or possible cross contamination from laboratory handling. Further, the unique double filtration system avoids any risks of Pulmonary Emboli (PE) or problems due to particulate matter. The CSN has over the last 4 years researched and designed equipment that supports new requirements supported by the FDA/TGA. As the CSN system is a closed sterile surgical system it can be done in a doctors office and adheres to FDA/TGA regulations.

IRB STUDIES- Areas of study by the Cell Surgical Network include Orthopedics, Urology, Neurology, Cardiac/Pulmonary, Auto-Immune Diseases, Lichen Sclerosis, Ophthalmology. See http://www.stemcellrevolution.com

JOINING CELL SURGICAL NETWORK - Physicians interested in participating in the Cell Surgical Network please contact Chris Lindholm for more information by emailing clindholm(at)cellsurgicalnetwork(dot)com or phone 800-231-0407.

See original here:
Cell Surgical Network Opening in Australia

Japan stem cell scientist stands by 'phoney' research

53 minutes ago

A young female scientist accused of fabricating data made a tearful apology live on Japanese television Wednesday for "mistakes" in her research, but insisted her ground-breaking conclusions on stem cells were accurate.

Haruko Obokata, 30, blamed her youth and inexperience for errors in her methodology, but said she had managed to create the building-block cells capable of growing into the specialised cells of the brain, liver, heart or kidneys.

"I apologise with my whole heart to my co-authors... and many others for causing trouble because of my insufficient efforts, ill-preparedness and unskilfulness," a visibly shaken Obokata told a press conference.

"To many people there may be too many unbelievable mistakes, but that does not affect the conclusion," she said.

Obokata was feted as a modern-day Marie Curie after unveiling research that showed a simple way to re-programme adult cells to become a kind of stem cell.

So-called Stimulus-Triggered Acquisition of Pluripotency (STAP) cells were hailed as a breakthrough that could provide a ready supply of the base material for much-needed transplant tissue at minimal cost.

Campaigners said it represented a leap forward in the fight against degenerative diseases.

Her profilea young woman in a world dominated by middle-aged menwas seized on by Japan's media, which was charmed by eccentricities that included her insistence on wearing a housewife's apron in the laboratory, instead of a white coat.

But within weeks of her paper being published in the prestigious journal Nature, questions began to emerge, with fellow scientists saying they were unable to replicate her results.

See the original post here:
Japan stem cell scientist stands by 'phoney' research

Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

A doctor offering stem cell therapy may face charges for the death of a cancer patient who allegedly underwent treatment similar to that administered to former president and incumbent Pampanga Rep. Gloria Macapagal-Arroyo.

This was after it was found out that she is not a licensed doctor in the Philippines.

A report on GMA News TV's "News To Go" on Wednesday said a complaint has been filed against Dr. Antonia Carandang-Park at the National Bureau of Investigation (NBI) by Bernard Tan, who claims that his daughter, Kate, died after going through the said alternative treatment.Cancer patient Kate Tan received stem cell therapy from Dr. Antonia Carandang-Park, Gloria Arroyo's doctor.

Park owns the Tagaytay-based Green & Young Health and Wellness Center where Arroyoburdened by persistent trouble with her cervical spinesought treatment in 2012.

In an interview with GMA News, Tan said his daughter, who had Hodgkin's lymphoma (a type of cancer of the blood), was given "the same treatment that [Park] did with Gloria," which included "juicing diet, vegetable diet... acupuncture coffee enema, at 'yun na nga, stem cell."

Stem cell therapy introduces new adult stem cells into damaged tissue in order to treat disease or injury.

"Ang sabi niya, 'Give me three months, magaling na 'yan,'" Tan told GMA News. He added that his family was easily convinced to take their daughter to Park's wellness center because "Presidente na ng Pilipinas ang pumunta doon."

"Siguro naman na-scrutinize na nila 'yan, na-background check na nila 'yan," he said. "Kumbaga, 'yung credibility no'n, nag-build up na."

Kate was fed nothing but bananas and vegetable juices for three months, and had eight rounds of "embryonic" stem cell treatment, he said.

However, the 23-year-old lost even more weight, prompting the family to seek the assistance of a different doctor. Kate had eight rounds of 'embryonic' stem cell treatment, her father Bernard Tan said.Seven months later, in July 2013, Kate passed away.

Follow this link:
Gloria Arroyos stem cell therapy doc blamed for cancer patient's death

NIH Stem-Cell Program Closes

The director of the agency's Center for Regenerative Medicine resigned on March 28 after just one clinical-trial award had been made

Therapies based on induced pluripotent stem cells, here differentiating into retinal cells on a scaffold, were the focus of the Center for Regenerative Medicine. Credit: NIH

Stem-cell researchers at the National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agencys Center for Regenerative Medicine (CRM). The intramural programs director, stem-cell biologist Mahendra Rao, left the NIH, in Bethesda, Maryland, on 28March, and the centers website was taken down on 4 April. Although no official announcement had been made at the timeNaturewent to press, NIH officials say that they are rethinking how they will conduct in-house stem-cell research.

Researchers affiliated with the center say that they have been left in the dark. When contacted byNatureon 7April, George Daley, a stem-cell biologist at Harvard Medical School in Boston, Massachusetts, and a member of the centers external advisory board, said that he had not yet been told of Raos departure or the centers closure.

The CRM was established in 2010 to centralize the NIHs stem-cell program. Its goal was to develop useful therapies from induced pluripotent stem (iPS) cells adult cells that have been converted into embryonic-like stem cells and shepherd them towards clinical trials and regulatory approval. Its budget was intended to be $52million over seven years.

Rao took the helm in 2011. Relations seem to have soured last month owing to an NIH decision to award funding to only one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear. He says that he had hoped that five trials would be funded, especially because the center had already sorted out complex issues relating to tissue sources, patents and informed consent.

James Anderson, director of the NIHs Division of Program Coordination, Planning, and Strategic Initiatives, which administered the CRM, counters that only one application that made by Kapil Bharti of the National Eye Institute in Bethesda and his colleagues received a high enough score from an external review board to justify continued funding. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years. Several other proposals, which involved the treatment of cardiac disease, cancer and Parkinsons disease, will not receive funding to ready them for clinical trials. Anderson stresses that Bhartis trial will not be affected by the CRMs closure.

Other human iPS-cell trials are further along. For example, one on macular degeneration designed by Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe, Japan, began recruiting patients last August.

Anderson says that the CRM will not continue in its current form. The field is moving so fast that we need to rethink. To that end, the NIH plans to hold a workshop in May to gather stem-cell researchers together and decide what to do with the program and its remaining budget. To me thats just smart science, he says. If somethings not on track you dont keep spending money on it.

One option could be to allow CRM projects to be absorbed by the National Center for Advancing Translational Sciences, an NIH institute established in 2011 to translate basic research into therapies. But Anderson says that participants at the workshop will also discuss whether the NIH needs to replace the CRM with another dedicated stem-cell program.

Original post:
NIH Stem-Cell Program Closes

Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014

New York, NY (PRWEB) April 09, 2014

The Stem Cell Institute, located in Panama City, Panama, will present an informational umbilical cord stem cell therapy seminar on Saturday, May 17, 2014 in New York City at the New York Hilton Midtown from 1:00 pm to 4:00 pm.

Speakers include:

Neil Riordan PhD Clinical Trials: Umbilical Cord Mesenchymal Stem Cell Therapy for Autism and Spinal Cord Injury

Dr. Riordan is the founder of the Stem Cell Institute and Medistem Panama Inc.

Jorge Paz-Rodriguez MD Stem Cell Therapy for Autoimmune Disease: MS, Rheumatoid Arthritis and Lupus

Dr. Paz is the Medical Director at the Stem Cell Institute. He practiced internal medicine in the United States for over a decade before joining the Stem Cell Institute in Panama.

Light snacks will be served afterwards. Our speakers and stem cell therapy patients will also be on hand to share their personal experiences and answer questions.

Admission is free but space in limited and registration is required. For venue information and to register and reserve your tickets today, please visit: http://www.eventbrite.com/e/stem-cell-institute-seminar-tickets-11115112601 or call Cindy Cunningham, Patient Events Coordinator, at 1 (800) 980-7836.

About Stem Cell Institute Panama

Excerpt from:
Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in New York City May 17th, 2014

NIH stem-cell programme closes

Bradley J. Fikes

Stem-cell biologist Mahendra Rao expected five projects to receive support to set up clinical trials.

Stem-cell researchers at the US National Institutes of Health (NIH) have been left frustrated and confused following the demise of the agencys Center for Regenerative Medicine (CRM). The intramural programmes director, stem-cell biologist Mahendra Rao, left the NIH, in Bethesda, Maryland, on 28March, and the centres website was taken down on 4 April. Although no official announcement had been made at the time Nature went to press, NIH officials say that they are rethinking how they will conduct in-house stem-cell research.

Researchers affiliated with the centre say that they have been left in the dark. When contacted by Nature on 7April, George Daley, a stem-cell biologist at Harvard Medical School in Boston, Massachusetts, and a member of the centres external advisory board, said that he had not yet been told of Raos departure or the centres closure.

The CRM was established in 2010 to centralize the NIHs stem-cell programme. Its goal was to develop useful therapies from induced pluripotent stem (iPS) cells adult cells that have been converted into embryonic-like stem cells and shepherd them towards clinical trials and regulatory approval. Its budget was intended to be $52million over seven years.

Rao took the helm in 2011. Relations seem to have soured last month owing to an NIH decision to award funding to only one project aiming to move iPS cells into a clinical trial. Rao says he resigned after this became clear. He says that he had hoped that five trials would be funded, especially because the centre had already sorted out complex issues relating to tissue sources, patents and informed consent.

James Anderson, director of the NIHs Division of Program Coordination, Planning, and Strategic Initiatives, which administered the CRM, counters that only one application that made by Kapil Bharti of the National Eye Institute in Bethesda and his colleagues received a high enough score from an external review board to justify continued funding. The team aims to use iPS cells to treat age-related macular degeneration of the retina, and hopes to commence human trials within a few years. Several other proposals, which involved the treatment of cardiac disease, cancer and Parkinsons disease, will not receive funding to ready them for clinical trials. Anderson stresses that Bhartis trial will not be affected by the CRMs closure.

NIH

Therapies based on induced pluripotent stem cells, here differentiating into retinal cells on a scaffold, were the focus of the Center for Regenerative Medicine.

Other human iPS-cell trials are further along. For example, one on macular degeneration designed by Masayo Takahashi at the RIKEN Center for Developmental Biology in Kobe, Japan, began recruiting patients last August.

Read more:
NIH stem-cell programme closes

Stem Cells Show Promise for Stroke Recovery

Brenda Goodman HealthDay Reporter Posted: Monday, April 7, 2014, 4:00 PM

MONDAY, April 7, 2014 (HealthDay News) -- In an early test, researchers report they've safely injected stem cells into the brains of 18 patients who had suffered strokes. And two of the patients showed significant improvement.

All the patients saw some improvement in weakness or paralysis within six months of their procedures. Although three people developed complications related to the surgery, they all recovered. There were no adverse reactions to the transplanted stem cells themselves, the study authors said.

What's more, the researchers said, two patients experienced dramatic recoveries almost immediately after the treatments.

Those patients, who were both women, started to regain the ability to talk and walk the morning after their operations. In both cases, they were more than two years past their strokes, a point where doctors wouldn't have expected further recovery.

The results have encouraged researchers to plan larger and longer tests of the procedure, which uses stem cells cultured from donated bone marrow.

An expert who was not involved in the research called it a promising first step.

"It's a small, early human study. It takes multiple steps to get to something clinically useful, and this is a nice, early step," said Dr. Steven Cramer, clinical director of the Stem Cell Research Center at the University of California, Irvine.

The findings were to be presented Monday at the American Association of Neurological Surgeons annual meeting, in San Francisco. The results of studies presented at meetings are considered preliminary until they've been published in peer-reviewed medical journals.

Read more from the original source:
Stem Cells Show Promise for Stroke Recovery